Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer in China.
Journal Information
Full Title: Risk Manag Healthc Policy
Abbreviation: Risk Manag Healthc Policy
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Health Care Sciences & Services
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Disclosure The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."
"This research was supported by the Science and Technology Development Program of Medical and Health from Shandong Province (202102040505) and Nursery science research projects of affiliated hospital of Jining medical university (MP-MS-2021-001)."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025